The U.S. Court of Appeals on Wednesday stayed an order that would bar Regeneron Pharmaceuticals and Sanofi from selling their cholesterol drug Praluent.The drugmakers can continue to sell the medication as they undergo the appeals process, reports Reuters.
A district judge blocked sales of Praluent Jan. 5 after Amgen won a lawsuit against Regeneron and Sanofi, alleging Praluent infringed on patents for its own cholesterol drug Repatha.
Joseph LaRosa, JD, general counsel for Regeneron, said the company would continue to defend its case through the appeals process, according to the report. Sanofi spokeswoman Ashleigh Koss told Reuters via email the company was happy the court stayed the order since it gives U.S. patients continued access to Praluent during the appeals process.
Amgen spokeswoman Kristen Davis told Reuters the company respected the court's decision but felt confident it would win against Regeneron and Sanofi's appeal.
The order would have gone into effect Feb. 21, according to the report.
More articles on supply chain:
Supply chain tip of the week: 9 questions to test your inventory management IQ
10 statistics on drug, device recalls in Q4
6 quotes from Pfizer CEO on Trump, drug prices and more